title: [Intracavernous self-injection in impotence].
abstract: On the basis of new diagnostic methods, 50 to 80% of impotent men show organic changes which are potentially responsible for erectile dysfunction. In our institution 409 consecutive patients have been submitted to the programme of intracavernous self-injection of papaverine. In 11% of the patients erectile function was normalized after a series of self-injections. 25% use papaverine regularly at home, and 64% discontinued the self-injections. Many of these patients did not accept this form of therapy. Side effects are rare and harmless. Early information about the intracavernous self-injection therapy by the physician can help to avoid unnecessary investigations.
authors.affiliation: Urologische Universitätsklinik, Inselspital, Bern.
authors.forename: A
authors.initials: A
authors.lastname: Sieber
authors.forename: M
authors.initials: M
authors.lastname: Schnyder von Wartensee
authors.forename: H J
authors.initials: HJ
authors.lastname: Thönen
authors.forename: U E
authors.initials: UE
authors.lastname: Studer
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D007172:Erectile Dysfunction / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage*; D012646:Self Administration; D013737:Testis
chemical_list: D010208:Papaverine
vernacular_title: Schwellkörper--Autoinjektionstherapie (= SKAT) bei Impotenz.